Agios Pharmaceuticals (AGIO) Issues Earnings Results, Misses Expectations By $0.16 EPS
Agios Pharmaceuticals (NASDAQ:AGIO) announced its quarterly earnings data on Wednesday. The biopharmaceutical company reported ($1.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.65) by ($0.16), Bloomberg Earnings reports. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 69.64% and a negative net margin of 506.39%. Agios Pharmaceuticals’s revenue for the quarter was down 56.7% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($1.34) earnings per share.
Agios Pharmaceuticals (AGIO) opened at $76.53 on Wednesday. The stock has a market capitalization of $4,285.58, a PE ratio of -12.21 and a beta of 2.12. Agios Pharmaceuticals has a 12-month low of $45.11 and a 12-month high of $82.96.
In related news, insider Carman Alenson sold 2,150 shares of the business’s stock in a transaction that occurred on Friday, January 12th. The stock was sold at an average price of $75.00, for a total value of $161,250.00. Following the completion of the transaction, the insider now directly owns 2,150 shares in the company, valued at approximately $161,250. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO David P. Schenkein sold 23,572 shares of the business’s stock in a transaction that occurred on Friday, January 26th. The shares were sold at an average price of $81.09, for a total value of $1,911,453.48. Following the completion of the transaction, the chief executive officer now owns 23,572 shares of the company’s stock, valued at $1,911,453.48. The disclosure for this sale can be found here. Insiders have sold a total of 183,114 shares of company stock valued at $13,866,025 over the last 90 days. Corporate insiders own 5.43% of the company’s stock.
AGIO has been the subject of a number of research reports. Oppenheimer reiterated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Canaccord Genuity set a $90.00 price objective on Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Credit Suisse Group boosted their target price on Agios Pharmaceuticals from $61.00 to $66.00 and gave the stock an “outperform” rating in a research report on Thursday, November 2nd. Finally, BidaskClub lowered Agios Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, December 16th. Two research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Agios Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $77.64.
Agios Pharmaceuticals Company Profile
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.